Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study DOI Creative Commons

Ulrich Jaeger,

Ingrid Simonitsch‐Klupp,

Patrick Klammer

et al.

Frontiers in Hematology, Journal Year: 2024, Volume and Issue: 3

Published: March 28, 2024

Background Patients with diffuse large B-cell lymphoma (DLBCL) relapsing early (within 12 months) or primary refractory to induction therapy rituximab (R) and CHOP have a poor prognosis. We therefore initiated study obinutuzumab venetoclax. Study design methods Twenty-one patients DLBCL (relapsed within months refractory), detectable Bcl-2 protein expression, CD20 positivity were included in this prospective single-arm between 2016 2021. Obinutuzumab was administered i.v. at dose of 1,000 mg on days 1, 8, 15 cycle 1 day each the following 21-day cycles. Venetoclax given 800 daily p.o. continuously. Treatment repeated for up three Eligible planned either proceed cellular therapies receive nine cycles maintenance. The endpoint objective response rate (ORR) after (Eudract Nr. 2016-001760-10 NCT02987400). Results (median age, 64 years) relapsed one ( N = 11) four previous lines included. majority received obinutuzumab/venetoclax (range, 1–8). regimen well tolerated manageable cytopenias infections. Severe adverse events related treatment observed 9.5%. ORR 38.1% (8/21 patients) best five complete remissions (CRs; 23.8%) partial (PRs; 14.2%). (45% ORR) not met. Response duration 83.3% 84 days, progression-free survival 38.8% 25.9% 168 median overall 169.1 weeks. All deaths due underlying disease. Seven became eligible autologous transplant. Overall, (42.8%) 11 (5 ASCT 6 CAR-T). Three went directly from CAR-T therapy. had successful peripheral stem cell T-cell harvests. Characteristics responders include disease (response rate, 54%), very good R-IPI (7 8), low number 1). Conclusion Obinutuzumab/venetoclax represents an effective chemo-free relapse toxicity that can be followed by therapies, particularly cells.

Language: Английский

Interplay between NETosis and the lncRNA-microRNA regulatory axis in the immunopathogenesis of cancer DOI

Nisreen Salah Majeed,

Mohammed H. Mohammed,

Zainab Amer Hatem

et al.

Journal of Physiology and Biochemistry, Journal Year: 2025, Volume and Issue: unknown

Published: May 13, 2025

Language: Английский

Citations

0
Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B study DOI Creative Commons

Ulrich Jaeger,

Ingrid Simonitsch‐Klupp,

Patrick Klammer

et al.

Frontiers in Hematology, Journal Year: 2024, Volume and Issue: 3

Published: March 28, 2024

Background Patients with diffuse large B-cell lymphoma (DLBCL) relapsing early (within 12 months) or primary refractory to induction therapy rituximab (R) and CHOP have a poor prognosis. We therefore initiated study obinutuzumab venetoclax. Study design methods Twenty-one patients DLBCL (relapsed within months refractory), detectable Bcl-2 protein expression, CD20 positivity were included in this prospective single-arm between 2016 2021. Obinutuzumab was administered i.v. at dose of 1,000 mg on days 1, 8, 15 cycle 1 day each the following 21-day cycles. Venetoclax given 800 daily p.o. continuously. Treatment repeated for up three Eligible planned either proceed cellular therapies receive nine cycles maintenance. The endpoint objective response rate (ORR) after (Eudract Nr. 2016-001760-10 NCT02987400). Results (median age, 64 years) relapsed one ( N = 11) four previous lines included. majority received obinutuzumab/venetoclax (range, 1–8). regimen well tolerated manageable cytopenias infections. Severe adverse events related treatment observed 9.5%. ORR 38.1% (8/21 patients) best five complete remissions (CRs; 23.8%) partial (PRs; 14.2%). (45% ORR) not met. Response duration 83.3% 84 days, progression-free survival 38.8% 25.9% 168 median overall 169.1 weeks. All deaths due underlying disease. Seven became eligible autologous transplant. Overall, (42.8%) 11 (5 ASCT 6 CAR-T). Three went directly from CAR-T therapy. had successful peripheral stem cell T-cell harvests. Characteristics responders include disease (response rate, 54%), very good R-IPI (7 8), low number 1). Conclusion Obinutuzumab/venetoclax represents an effective chemo-free relapse toxicity that can be followed by therapies, particularly cells.

Language: Английский

Citations

0